TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04358146: Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula: a Double-blind, Randomized, Controlled, International, Multi-centric Clinical Trial

Sponsor: United Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 346 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,390,400

Rescue Site Savings

+$1,593,600

Unlock Full NCT04358146 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04358146 Rescue Dossier →